Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Spero R. Cataland, Paul Coppo, Marie Scully, Bernhard Lämmle

Blood (2024) 144 (11): 1143–1152.

https://doi.org/10.1182/blood.2023022277

Published: 2024

Journal Articles

Relapse and iTTP: beyond the ADAMTS13 activity

Spero R. Cataland

Blood (2024) 143 (25): 2567–2568.

https://doi.org/10.1182/blood.2024024684

Published: 2024

Journal Articles

Race, rituximab, and relapse in TTP

Blood (2022) 140 (12): 1335–1344.

https://doi.org/10.1182/blood.2022016640

Published: 2022

Includes: Supplemental data

Journal Articles

How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge

Frank Akwaa, Ana Antun, Spero R. Cataland

Blood (2022) 140 (5): 438–444.

https://doi.org/10.1182/blood.2021014514

Published: 2022

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD)

Matthew Bostic, BS, MS, Qiuhong Zhao, MS, Sarah A Wall, MD, Spero R Cataland, MD, Sumithira Vasu, MD MBBS

Blood (2018) 132 (Supplement 1): 4572.

https://doi.org/10.1182/blood-2018-99-114892

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Paul Knöbl, MD PhD, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2018-99-112174

Published: 2018

Journal Articles

The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis

Camila Masias, Spero R. Cataland

Blood (2018) 132 (9): 903–910.

https://doi.org/10.1182/blood-2018-02-791533

Published: 2018

Journal Articles

A Descriptive Analysis of the Demographics and Presenting Symptoms of Patients in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry

Elizabeth Davis, Ana G. Antun, MD, Lisa Baumann Kreuziger, MD MS, J. Evan Sadler, MD PhD, Spero R Cataland, MD, Meera Sridharan, MD, Todd Clover, MD, Andrew Johnson, MD, Keith McCrae, MD, Shruti Chaturvedi, MBBS,MS, Ronald S. Go, MD, Ming Yeong Lim, MBBChir, Marshall A. Mazepa, MD

Blood (2017) 130 (Supplement 1): 1049.

https://doi.org/10.1182/blood.V130.Suppl_1.1049.1049

Published: 2017

Journal Articles

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Blood (2017) 130 (Supplement 1): 1932.

https://doi.org/10.1182/blood.V130.Suppl_1.1932.1932

Published: 2017

Journal Articles

Factors Associated with Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Results from the United States Thrombotic Microangiopathy TTP Registry

Todd Clover, MD MS, Ronald S. Go, MD, Ana G. Antun, MD, Spero R Cataland, MD, Shruti Chaturvedi, MBBS,MS, Elizabeth Davis, Andrew Johnson, MD, Ming Yeong Lim, MBBChir, Meera Sridharan, MD, Keith McCrae, MD, J. Evan Sadler, MD PhD, Marshall A. Mazepa, MD, Lisa Baumann-Kreuziger, MS MD

Blood (2017) 130 (Supplement 1): 3624.

https://doi.org/10.1182/blood.V130.Suppl_1.3624.3624

Published: 2017

Journal Articles

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, MD, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD, Ara Metjian, MD, Javier de la Rubia, MD, Katerina Pavenski, MD, Filip Callewaert, PhD, Debjit Biswas, PhD, Hilde De Winter, MD, Robert K. Zeldin, MD

Blood (2017) 130 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-1.LBA-1

Published: 2017

Journal Articles

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Meera Sridharan, MD, Ana G Antun, MD, Lisa Baumann Kreuziger, Assistant Professor. MD MS, Spero R Cataland, MD, Shruti Chaturvedi, MBBS,MS, Todd Clover, MD, Elizabeth Davis, Andrew Johnson, MD, Keith McCrae, MD, Ming Yeong Lim, MBBChir, J. Evan Sadler, MD PhD, Marshall A. Mazepa, MD, Ronald S Go, MD

Blood (2017) 130 (Supplement 1): 3620.

https://doi.org/10.1182/blood.V130.Suppl_1.3620.3620

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Prediction of Relapse Based on Remission ADAMTS13 Activity in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias Castanon, MD, Clare Stevens, BS/CCRP, Lauren Jay, Haiwa Wu, Michael McGookey, Jian Chen, MD, James N. George, MD, Shangbin Yang, PhD, Spero R Cataland, MD

Blood (2017) 130 (Supplement 1): 4843.

https://doi.org/10.1182/blood.V130.Suppl_1.4843.4843

Published: 2017

Journal Articles

None of the above: thrombotic microangiopathy beyond TTP and HUS

Camila Masias, Sumithira Vasu, Spero R. Cataland

Blood (2017) 129 (21): 2857–2863.

https://doi.org/10.1182/blood-2016-11-743104

Published: 2017

Journal Articles

No Major Differences in Outcomes Between the Initial and Relapse Episodes in Patients with Thrombotic Thrombocytopenic Purpura: The Experience from the Ohio State University Registry

Camila Masias Castanon, MD, Haiwa Wu, Michael McGookey, Lauren Jay, Haifeng Wu, MD, Spero R Cataland, MD, Shangbin Yang, PhD

Blood (2016) 128 (22): 2544.

https://doi.org/10.1182/blood.V128.22.2544.2544

Published: 2016

NARROW

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Relapse and iTTP: beyond the ADAMTS13 activity

Race, rituximab, and relapse in TTP

How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge

Redefining outcomes in immune TTP: an international working group consensus report

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD)

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis

A Descriptive Analysis of the Demographics and Presenting Symptoms of Patients in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry

Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab

Factors Associated with Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Results from the United States Thrombotic Microangiopathy TTP Registry

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

The Impact of Detectable ADAMTS13 Inhibitor on the Clinical Presentation and Outcome of Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Analysis Using the United States Thrombotic Microangiopathy (USTMA) Clinical Registry

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Prediction of Relapse Based on Remission ADAMTS13 Activity in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

None of the above: thrombotic microangiopathy beyond TTP and HUS

No Major Differences in Outcomes Between the Initial and Relapse Episodes in Patients with Thrombotic Thrombocytopenic Purpura: The Experience from the Ohio State University Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only